Across ATL, Sézary syndrome, COVID-19, and psoriasis, our analysis suggests that Gal-9 functions as a recurring immunomodulator linking neutrophil activation to altered T-cell receptor (TCR) signaling. This evidence concerns the gene LGALS9 and COVID-19.